Kevin Chen
Wuxi international life science innovation campus
Investment promotion managerDenise Chen
GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.
GIG
PartnerPaul Chen
Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Reistone Biopharma
Chief of StaffMr Jim Chen
Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion. It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas. Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.
For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.
Tianjin chasesun pharmaceutical co ltd
Investment ManagerMr. Mark Chen
Kintor Pharmaceuticals
BD DirectorHaipeng Cheng
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.
Sangel Capital
Mr. Chris Chow
Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.